The first new mechanism for schizophrenia in 70 years launched in late 2024. Now, as we enter Q1 2026, we have enough data to assess what Cobenfy means for patients, prescribers, and investors. The verdict: a quiet revolution is underway—one that will take years to fully materialize but may ultimately transform how we treat serious mental illness.

Bristol Myers Squibb’s Cobenfy (xanomeline/trospium chloride) was approved by the FDA in September 2024 and launched commercially in late October. It was not another “me-too” dopamine blocker. It was the first antipsychotic to work through muscarinic receptor agonism—a completely different approach to the disease. Here is the Q1 2026 status report.

Real-World Adoption: Steady, Not Explosive

Let’s start with the numbers. Cobenfy generated $43 million in Q3 2025 sales, up from $35 million in Q2 and $27 million in Q1. For the full year through Q3, the drug had brought in $105 million. Weekly prescriptions reached approximately 1,800 by mid-year, with over 30,000 total scripts filled since launch.

These are respectable numbers for a specialty psychiatric launch, but they fall short of the explosive uptake that some investors hoped for when BMS paid $14 billion to acquire Karuna Therapeutics in early 2024. JPMorgan analyst Chris Schott projects Cobenfy sales reaching $5 billion by 2030, with peak sales potential in the $10 billion range across multiple indications. But that trajectory requires patience.

Why the Slow Burn?

The challenge is not the drug’s efficacy or safety profile—physician feedback has been positive on both fronts. The challenge is what BMS calls “deeply ingrained D2 prescribing habits.” For 70 years, every schizophrenia drug has worked by blocking dopamine receptors. Psychiatrists are trained on this mechanism, comfortable with these drugs, and know how to manage their side effects.

“We’re out with our team educating customers on Cobenfy’s differentiated profile, and we’re breaking reflexive prescribing habits. That’s going to take some time.”

— Adam Lenkowsky, BMS Chief Commercialization Officer

The market structure compounds this inertia. More than a dozen antipsychotics are already approved for schizophrenia, many available as inexpensive generics. Over 80% of schizophrenia patients are on Medicaid or Medicare, creating institutional pressure to try cheaper alternatives first. Cobenfy must prove itself in a system that defaults to generic risperidone or olanzapine before considering a novel branded therapy.

This is not a failure of the drug; it is a feature of the market. Novel mechanisms in entrenched therapeutic areas always face adoption curves measured in years, not quarters. The relevant question is whether Cobenfy will ultimately capture the patients who need something different—and on that metric, the early signals are encouraging.

Patient Experience: The True Differentiator

The reason Cobenfy matters—and the reason BMS paid $14 billion for it—is not that it works better than existing drugs on standard efficacy measures. It’s that it works differently, with a side effect profile that could fundamentally change treatment persistence.

The “Zombie Problem”

Traditional antipsychotics block dopamine D2 receptors throughout the brain. This reduces psychotic symptoms, but dopamine receptors are located in many brain regions unrelated to psychosis. The result is a constellation of side effects that patients often describe as making them feel like “zombies”: cognitive dulling, sedation, emotional blunting, movement disorders, and metabolic dysfunction.

The numbers are stark. Cardiovascular disease is the leading cause of death in people with schizophrenia, driven largely by antipsychotic-induced weight gain, diabetes, and metabolic syndrome. Extrapyramidal symptoms (EPS)—involuntary movements, muscle rigidity, tremors—affect a substantial proportion of patients and can be permanent (tardive dyskinesia). Many patients stop taking their medications specifically because of these side effects, leading to relapse, hospitalization, and the devastating cycle that characterizes poorly controlled schizophrenia.

Cobenfy’s Mechanistic Advantage

Cobenfy does not block dopamine receptors. Instead, it activates M1 and M4 muscarinic receptors in the brain, which indirectly modulates dopamine activity in the specific regions associated with psychotic symptoms—”turning off the spigot at the source,” as one researcher described it. This targeted approach explains the drug’s differentiated side effect profile:

• No significant weight gain: Clinical trials showed minimal weight changes, a stark contrast to drugs like olanzapine
• No extrapyramidal symptoms: No movement disorders, akathisia, or tardive dyskinesia risk
• No prolactin elevation: Avoids hormonal side effects common with D2 blockers
• Potential cognitive benefits: Muscarinic receptors are involved in learning and memory; early reports suggest Cobenfy may enhance rather than impair cognition

The side effects that do occur are primarily gastrointestinal—nausea, constipation, dyspepsia—and tend to resolve with continued treatment. The trospium component of the combination specifically exists to minimize these effects by blocking muscarinic receptors in the periphery without crossing the blood-brain barrier.

Early Clinical Experience: Psychiatrists report “positive surprise” on Cobenfy’s real-world tolerability. Patients describe improvement in positive symptoms, negative symptoms, and cognitive function—with particular benefit in patients who had failed or could not tolerate traditional antipsychotics.

The Persistence Opportunity

If Cobenfy delivers better tolerability in broad clinical practice, the implications are profound. Patients who stay on their medications have dramatically better outcomes than those who cycle on and off. A drug that patients actually want to take—because it doesn’t make them feel sedated, gain weight, or develop movement disorders—could change the trajectory of disease for the estimated 1.6 million Americans with schizophrenia.

This is why early physician feedback matters as much as quarterly sales figures. BMS reports that doctors who have tried Cobenfy are seeing exactly what the clinical trials suggested: effective symptom control without the dopamine-mediated side effects that have plagued the class for seven decades.

What’s Next: The Alzheimer’s Psychosis Opportunity

Schizophrenia is Cobenfy’s first indication, but it may not be its largest. BMS believes Alzheimer’s disease represents the biggest market opportunity for the drug—and the company is betting heavily on that thesis.

The Hidden Epidemic

There are nearly 7 million Americans with Alzheimer’s disease. As the condition progresses, a substantial proportion—estimates range from 25% to 50%—develop psychosis: hallucinations, delusions, paranoia. These symptoms are devastating for patients and caregivers alike, often triggering institutionalization and accelerating decline.

Currently, there is no FDA-approved treatment for Alzheimer’s-related psychosis. Atypical antipsychotics are used off-label, but they carry a black box warning for increased mortality risk in elderly dementia patients. The need for a safe, effective treatment is enormous.

The ADEPT Program

BMS is running three Phase 3 trials—ADEPT-1, ADEPT-2, and ADEPT-4—evaluating Cobenfy in psychosis associated with Alzheimer’s disease. The company has said it needs two positive trials to file for FDA approval.

The program hit a setback in December 2025 when BMS announced that ADEPT-2 would require additional patient enrollment after the company identified “irregularities due to clinical trial execution at a small number of study sites.” The data, originally expected by year-end 2025, will now read out by the end of 2026. ADEPT-1 and ADEPT-4 remain on track for 2026 readouts as originally planned.

Importantly, the Data Monitoring Committee recommended continuing the trial after reviewing interim data—a signal that analysts interpreted positively. If there were no efficacy signal, why bother enrolling additional patients?

Blockbuster Math

The Alzheimer’s psychosis market is massive. With millions of patients and no approved treatment, even modest penetration could generate billions in revenue. BMS CFO David Elkins has described Alzheimer’s as the “really large market here,” with each indication—psychosis, agitation, cognition—representing multibillion-dollar potential.

If Cobenfy succeeds in Alzheimer’s psychosis, it would be the first drug specifically approved for the condition and the first muscarinic-based therapy for any Alzheimer’s symptom. Combined with ongoing trials in Alzheimer’s agitation, Alzheimer’s cognition, bipolar disorder, and autism spectrum disorder, BMS has positioned Cobenfy for data readouts every year through the end of the decade.

Why This Matters

For Patients and Families

Cobenfy represents something genuinely new: a schizophrenia treatment that doesn’t force patients to choose between controlling their symptoms and feeling like themselves. For the millions of people who have cycled through antipsychotic after antipsychotic—gaining weight, developing movement disorders, losing cognitive sharpness—a drug that works differently offers real hope.

If the Alzheimer’s trials succeed, Cobenfy could transform care for dementia patients and their caregivers. Psychosis is one of the most distressing symptoms of Alzheimer’s progression, and the current treatment options are inadequate and potentially dangerous.

For Clinicians

Cobenfy is not a replacement for existing antipsychotics—it’s an expansion of the toolkit. For patients who respond well to D2 blockers with manageable side effects, there’s no reason to switch. But for patients who cannot tolerate traditional antipsychotics, who have failed multiple agents, or who are particularly vulnerable to metabolic or movement-related side effects, Cobenfy offers a mechanistically distinct option.

Early clinical experience suggests the drug may have particular value in patients with prominent negative symptoms (social withdrawal, blunted affect) and cognitive deficits—areas where traditional antipsychotics have always fallen short.

For Investors

Cobenfy’s slow launch trajectory reflects the reality of novel mechanisms in entrenched markets, not a failure of the drug. BMS paid $14 billion for Karuna because of Cobenfy’s long-term potential, not because it expected immediate blockbuster sales in schizophrenia.

The key catalysts are the ADEPT program readouts in 2026. Two positive trials would open the Alzheimer’s psychosis market—a potentially transformative opportunity. A successful expansion into additional neuropsychiatric indications could justify the premium BMS paid and then some.

For now, Cobenfy is what BMS says it is: “delivering steady growth.” The question is whether that steady growth becomes an inflection point when Alzheimer’s data arrive.

The Quiet Revolution

Seventy years is a long time to wait for a new idea in psychiatry. From chlorpromazine in the 1950s through the atypical antipsychotics of the 1990s and 2000s, every schizophrenia drug has worked by the same basic mechanism: blocking dopamine. Cobenfy breaks that paradigm.

The revolution will not be televised—or at least, it won’t show up in explosive quarterly sales figures. Changing prescribing habits takes time. Proving long-term outcomes takes time. Expanding into new indications takes time.

But for patients who have never had an option that didn’t come with devastating side effects, for caregivers managing loved ones with Alzheimer’s psychosis, for psychiatrists who have watched patients fail drug after drug—the wait may finally be over.

Cobenfy’s first year was steady. Its second year, with ADEPT data expected, could be transformational. And the decade ahead could vindicate BMS’s $14 billion bet on a completely new way to treat serious mental illness.

Related BioMed Nexus Coverage

Neuroscience and Psychiatry

• IntraBio Phase 3 Success in Ataxia-Telangiectasia — Functional endpoints in rare neurological disease
• FDA MRD Guidance Reshapes Oncology Development — Novel endpoint acceptance trends

Big Pharma Strategy

• BMS Commits $850M to Tumor-Activated T-Cell Engagers — BMS business development strategy
• JPM 2026 Coverage — Industry trends and deal flow

Market Analysis

• Retatrutide vs. CagriSema: The Triple Agonist Era — Novel mechanisms reshaping markets
• Post-JPM 2026: Capital Clearing and Earnings Pivot — Sector positioning

Subscribe to BioMed Nexus — Free

Daily biotech, medtech, and pharma intelligence for industry leaders.

Upgrade to BioMed Nexus Premium

Institutional-grade analysis including IPO allocation strategies, M&A probability modeling, thematic rotation frameworks, and policy implications.

Frequently Asked Questions: Cobenfy

What is Cobenfy and how is it different from other schizophrenia drugs?

Cobenfy (xanomeline/trospium chloride) is the first antipsychotic to work through muscarinic receptor agonism rather than dopamine receptor blockade. This novel mechanism means it avoids many side effects common to traditional antipsychotics, including weight gain, movement disorders, and cognitive dulling.

How much has Cobenfy sold in its first year?

Through Q3 2025, Cobenfy generated $105 million in cumulative sales, including $43 million in Q3 2025. Weekly prescriptions reached approximately 1,800, with over 30,000 total scripts filled since launch.

Why isn’t Cobenfy selling faster?

Cobenfy faces “deeply ingrained” prescribing habits in a market dominated by generic antipsychotics. Most schizophrenia patients are on Medicaid or Medicare, creating pressure to try cheaper alternatives first. Novel mechanisms in entrenched therapeutic areas typically have adoption curves measured in years.

What are Cobenfy’s main side effects?

The most common side effects are gastrointestinal (nausea, constipation, dyspepsia) and tend to resolve with continued treatment. Importantly, Cobenfy does not cause weight gain, movement disorders, or cognitive impairment—the side effects that lead many patients to stop traditional antipsychotics.

What is Alzheimer’s psychosis and why is it important for Cobenfy?

Up to half of Alzheimer’s patients develop psychosis (hallucinations, delusions) as their disease progresses. There is currently no FDA-approved treatment. BMS is running three Phase 3 trials (ADEPT program) evaluating Cobenfy for this indication, with readouts expected by end of 2026.

What happened with the ADEPT-2 trial?

BMS identified site execution irregularities at a small number of trial sites and is enrolling additional patients after consulting with the FDA. The Data Monitoring Committee recommended continuing the trial, which analysts interpreted as a positive sign. Data is now expected by end of 2026.

What are analysts projecting for Cobenfy sales?

JPMorgan analyst Chris Schott projects Cobenfy sales reaching approximately $5 billion by 2030, with peak sales potential in the $10 billion range across multiple indications including schizophrenia, Alzheimer’s psychosis, bipolar disorder, and autism spectrum disorder.

BioMed Nexus provides daily intelligence for leaders in biotech, medtech, and pharma. This editorial deep dive is intended for context, not investment recommendation.